Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species
Markus Muttenthaler(The University of Queensland), Paul F. Alewood(The University of Queensland), Åsa Andersson, Sarah Arrowsmith(University of Liverpool), Han Sheng Chiu(The University of Queensland), Richard J. Lewis(AstraZeneca (Netherlands)), Susan Wray(University of Liverpool), Lotten Ragnarsson, Marta Busnelli(National Research Council), Christian W. Gruber(Medical University of Vienna), Inga D. Neumann(University of Regensburg), Rohit Menon(University of Regensburg), Jennifer R. Deuis(The University of Queensland), Nathan J. Palpant(The University of Queensland), Terry Smith(The University of Texas MD Anderson Cancer Center), Irina Vetter(Centre National de la Recherche Scientifique), Margaret O’Brien(National University of Ireland), Christian Bergmayr(Medical University of Vienna)
Cited by 77
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
|Nature Medicine|2015|2.8k
Methods Used to Evaluate Pain Behaviors in Rodents
|Frontiers in Molecular Neuroscience|2017|1.3k
Therapeutic potential of venom peptides
|Nature Reviews Drug Discovery|2003|786
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
|Frontiers in Molecular Neuroscience|2017|654